Joshua T Schiffer

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc New concepts in understanding genital herpes
    Joshua T Schiffer
    Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Institute and Program in Infectious Diseases, 1616 Eastlake Avenue, LE 500, Seattle, WA 98102, USA
    Curr Infect Dis Rep 11:457-64. 2009
  2. pmc Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract
    Joshua T Schiffer
    Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States Department of Medicine, University of Washington, Seattle, United States
    elife 2:e00288. 2013
  3. pmc Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA, USA Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Front Immunol 4:209. 2013
  4. pmc Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach
    Joshua T Schiffer
    Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Comput Biol 9:e1003131. 2013
  5. doi Rapid host immune response and viral dynamics in herpes simplex virus-2 infection
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Nat Med 19:280-90. 2013
  6. pmc Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA 98102, USA
    J Antimicrob Chemother 66:2593-600. 2011
  7. pmc The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Infect Dis 204:554-61. 2011
  8. pmc Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes
    Joshua T Schiffer
    Department of Medicine, Laboratory Medicine, Global Health Medicine, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 107:18973-8. 2010
  9. pmc Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Sci Transl Med 1:7ra16. 2009
  10. pmc Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation
    Joshua T Schiffer
    Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA
    Haematologica 94:1101-8. 2009

Detail Information

Publications21

  1. pmc New concepts in understanding genital herpes
    Joshua T Schiffer
    Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Institute and Program in Infectious Diseases, 1616 Eastlake Avenue, LE 500, Seattle, WA 98102, USA
    Curr Infect Dis Rep 11:457-64. 2009
    ..This fact highlights the importance of laboratory diagnostics for this lifelong infection, and the need for an HSV vaccine...
  2. pmc Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract
    Joshua T Schiffer
    Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States Department of Medicine, University of Washington, Seattle, United States
    elife 2:e00288. 2013
    ..We conclude that HSV-2 infection is characterized by extremely rapid virological growth and containment at multiple contemporaneous sites within genital epithelium. DOI:http://dx.doi.org/10.7554/eLife.00288.001...
  3. pmc Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA, USA Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Front Immunol 4:209. 2013
    ..These results highlight the complex co-dependent relationship between HSV-2 and tissue resident CD8+ lymphocytes during the course of natural infection. ..
  4. pmc Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach
    Joshua T Schiffer
    Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Comput Biol 9:e1003131. 2013
    ..We conclude by describing experiments that can be used to validate the model, which will in turn provide vital information for dose selection for potential curative trials in animals and ultimately humans. ..
  5. doi Rapid host immune response and viral dynamics in herpes simplex virus-2 infection
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Nat Med 19:280-90. 2013
    ..The fact that immune responses usually control viral replication in genital skin before lesions develop provides hope that enhancing such responses could lead to effective vaccines and immunotherapies...
  6. pmc Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA 98102, USA
    J Antimicrob Chemother 66:2593-600. 2011
    ..We sought to describe the impact of twice-daily aciclovir and famciclovir on shedding episodes...
  7. pmc The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Infect Dis 204:554-61. 2011
    ..Herpes simplex virus type 2 (HSV-2) reactivations in the genital tract are responsible for mucocutaneous lesions and transmission and manifest as discrete shedding episodes...
  8. pmc Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes
    Joshua T Schiffer
    Department of Medicine, Laboratory Medicine, Global Health Medicine, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 107:18973-8. 2010
    ..The model suggests that the rate of containment of infected cells by the peripheral mucosal immune system is the major driver of duration and severity of HSV-2 reactivation in the immunocompetent host...
  9. pmc Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Sci Transl Med 1:7ra16. 2009
    ..Frequent HSV-2 shedding episodes in humans are explained by nearly constant release of small numbers of viruses from neurons that terminate in the genital tract...
  10. pmc Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation
    Joshua T Schiffer
    Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA
    Haematologica 94:1101-8. 2009
    ....
  11. pmc Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials
    Christine Johnston
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    Lancet 379:641-7. 2012
    ..Skin and mucosal herpes simplex virus type 2 (HSV-2) shedding predominantly occurs in short subclinical episodes. We assessed whether standard-dose or high-dose antiviral therapy reduces the frequency of such shedding...
  12. pmc Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes
    Nicholas J Moss
    Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA
    J Virol 86:9952-63. 2012
    ..These data suggest that other immune cell subsets with alternate phenotypes or anatomical locations may be responsible for genital herpes control in chronically infected individuals...
  13. pmc Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2
    Ramzi A Alsallaq
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Sex Transm Dis 37:290-7. 2010
    ..The continuation of developing Herpes simplex virus type-2 (HSV-2) prophylactic vaccines requires parallel mathematical modeling to quantify the effect on the population of these vaccines...
  14. ncbi AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication
    Nicholas D Weber
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 9:e97579. 2014
    ..These results show that HBV-targeted ZFNs can efficiently inhibit active HBV replication and suppress the cellular template for HBV persistence, making them promising candidates for eradication therapy. ..
  15. pmc Targeted DNA mutagenesis for the cure of chronic viral infections
    Joshua T Schiffer
    Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA
    J Virol 86:8920-36. 2012
    ..We then review issues regarding persistence of HIV-1, HBV, and HSV that are relevant to eradication with genome-altering approaches...
  16. ncbi Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, WA, USA
    J R Soc Interface 11:20140160. 2014
    ..Many shedding episodes that result in transmission do not reach the threshold of clinical detection, because the ulcer remains very small, highlighting one reason why HSV-2 spreads so effectively within populations. ..
  17. pmc Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents
    Joshua T Schiffer
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Antimicrob Agents Chemother 57:5820-9. 2013
    ..Therefore, long half-life is a key characteristic of any agent that might fully suppress HSV-2 reactivations. ..
  18. pmc Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy
    Jeffrey Thomas Schouten
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 60:68-71. 2012
    ..Though HIV-1 viral load was 0.19 logs higher in HSV-2-positive versus HSV-2-negative persons, first and second phase clearance rates during antiretroviral therapy were equal between participants in these 2 groups...
  19. pmc CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence
    Lichen Jing
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Virol 87:2617-27. 2013
    ..We conclude that human memory CD4 T-cell responses show a pattern of pronounced immunodominance for both chronic and self-limited viral infections and that this pattern can persist over several decades in the absence of antigen...
  20. ncbi The majority of CD4+ T-cell depletion during acute simian-human immunodeficiency virus SHIV89.6P infection occurs in uninfected cells
    Laura Matrajt
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Virol 88:3202-12. 2014
    ..Mechanisms to limit the profound indirect killing effects associated with HIV infection may be associated with immune preservation and improved long-term survival...
  21. ncbi Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis
    Joshua T Schiffer
    Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA
    J Acquir Immune Defic Syndr 44:229-34. 2007
    ..6%. These results support early initiation of HAART in patients with AIDS, except when IRIS-related mortality rates are high...